Addex Therapeutics (ADXN) EBITDA (2018 - 2025)

Addex Therapeutics has disclosed EBITDA across 8 years of filings, most recently posting -$974990.3 for Q4 2025.

• EBITDA for Q4 2025 came in at -$974990.3, up 68.98% year-over-year; the trailing twelve-month figure through Dec 2025 was -$4.3 million (up 49.19% YoY), and the FY2025 annual result was -$3.4 million, down 15.7% from the prior year.
• EBITDA came in at -$974990.3 for Q4 2025 at Addex Therapeutics, down from -$869278.7 in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$718146.6 in Q3 2024 to a low of -$21.3 million in Q4 2022.
• The 5-year median for EBITDA is -$3.1 million (2023), against an average of -$4.5 million.
• Across the five-year window, EBITDA tumbled 100.87% in 2022 and jumped 88.13% in 2023, its largest moves.
• Addex Therapeutics' EBITDA stood at -$16.8 million in 2021, then retreated by 26.66% to -$21.3 million in 2022, then surged by 88.13% to -$2.5 million in 2023, then fell by 24.32% to -$3.1 million in 2024, then surged by 68.98% to -$974990.3 in 2025.
• The last three EBITDA figures came in at -$974990.3 (Q4 2025), -$869278.7 (Q3 2025), and -$884150.3 (Q2 2025), per Business Quant data.